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ABSTRACT
Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms
(EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative
symptom efficacy, less impaired cognition and lower risk of extrapyramidal syndromes. Aripiprazole, a new atypical antipsychotic drug,
displayed efficacy similar to risperidone and haloperidol in numerous clinical trials. Aripiprazole does not cause significant prolactin
elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Aripiprazole
is a study drug for treating schizophrenia and has a novel pharmacologic profile. Aripiprazole provides a new treatment option with
limited adverse effects for patients in need of antipsychotic therapy. The present study is a 4-week, open-labelled, randomized post-
marketing clinical study conducted using aripiprazole as the study drug. Fixed doses of 15mg of the drug were administered throughout
the study. A total of 249 patients with a primary diagnosis of schizophrenia or schizoaffective disorder were randomized. Efficacy
measures included the Positive And Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and general
psychopathology. Patients were evaluated for efficacy parameters at the end of 2nd week and also at the end of study.  Unlike the other
antipsychotics, aripiprazole was not associated with significant EPS, increase in body weight or increase in QTc interval. Aripiprazole,
effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective
disorder.
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Introduction
Schizophrenia is among the most serious of mental illnesses;
it causes great distress to patients and their families and
has a considerable social and economic impact. Globally it
affects approximately 1% of the population and is a major
cause of disability and is characterized by positive, negative
and cognitive symptoms (Murray CJ et al, 1996; Andreasson
NC, 2000). Positive symptoms are the most recognizable
and include auditory hallucinations, delusions, disorganized
thought, disorganized behavior, and catatonia. Negative
symptoms such as alogia, flattened affect, anhedonia, and
avolition are not as apparent, yet are equally disabling to
the patient’s functioning. A decrease in cognitive functioning
has been classified as a negative symptom, but is gaining
acceptance as another primary feature of the disease.
Antipsychotic medication is the main therapeutic intervention
for schizophrenia. Conventional agents have been found to
be effective in treating the positive symptoms of
schizophrenia by reducing or eliminating symptom
recurrence. Although the pathophysiology of the disease
has yet to be clearly defined, antipsychotic drug development
has been heavily influenced by the dopamine hypothesis,
(Seeman P et al, 1990) which states that dopamine
overactivity in the brain is responsible for the disease.
Evidence for this hypothesis includes the capacity of
antipsychotic drugs to block dopamine receptors in vivo
(Anden N et al, 1970) and in vitro (Creese I et al, 1976). In
addition, the clinical efficacy of antipsychotic drugs is highly
correlated with their ability to block dopamine D2 receptors
(Carlsson A, 1988; Emillen G et al, 1999).
The early agents for the treatment of psychosis, the “typical”
antipsychotics, were breakthrough therapies for the positive
symptoms of schizophrenia but were less effective in
treating the negative symptoms of the disease. In addition,
the D2 receptor antagonism of these drugs produced
unwanted side effects, such as extrapyramidal symptoms
(EPS) and hyperprolactinemia (Richelson E, 1999).
In attempts to meet these unmet needs, researchers have
explored the possibility of using dopamine D2 partial agonists
for the treatment of schizophrenia. (Lahti AC et al, 1998;
Ban TA, 2001; Iyer RN et al, 1998). The most recent class
of drugs, known as “atypical” antipsychotics, was first
recognized in the US with the introduction of clozapine in
1989 (Ban TA, 2001). These atypical antipsychotics,
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introduced in the mid-1990s, combined D2 blockade with
antagonism of serotonin 5-HT2A receptors and produced
significantly less EPS and hyperprolactinemia than the
typical antipsychotics. The atypical agents that have been
available in the US market after clozapine included
risperidone, olanzapine, quietiapine, and ziprasidone. These
agents focus mechanistically on antagonizing postsynaptic
dopamine – 2 (D2) receptors in the mesolimbic and
mesocortical dopaminergic tracts. These new medications
differ from the conventional agents by demonstrating clinical
efficacy while producing fewer extra-pyramidal symptoms
(EPS); they are beneficial in treating negative symptoms
and may also improve the neurocognitive deficits associated
with schizophrenia. Their mechanism also differs from that
of previously used drugs with greater affinity for antagonism
of post-synaptic serotonin – 2 (5-HT2) receptors and also
greater than the affinity for antagonism of D2 receptors.
However, different side effects have been seen with
individual agents, including weight gain and somnolence,
which can decrease compliance and persistency,
(Fleischhacker WW et al, 1999; Kurzthaler I et al, 2001)
leading to increased relapse. Thus, there is still an unmet
need for novel antipsychotic drugs that are better tolerated
than earlier typical agents and currently available atypical
medications. In addition, enhanced overall efficacy against
the positive symptoms, negative symptoms, and cognitive
dysfunction of schizophrenia remains an unmet medical
need.
Aripiprazole is a novel agent with a unique pharmacologic
profile that acts as a potent partial agonist at dopamine D2
receptors, a partial agonist at serotonin 5-HT1A receptors,
and an antagonist at 5-HT2A receptors. (Burris KD et al,
2002; Jordan S et al, 2002; McQuade RD et al, 2002). It
has been suggested that dopamine partial agonists maybe
capable of stabilizing the dopaminergic system without
inducing the hypodopaminergia that limits the tolerability of
currently available antipsychotics. (Carlsson A. et al, 2000;
Stahl SM, 2001) Aripiprazole acts as a functional antagonist
at D2 receptors under hyperdopaminergic conditions, but
exhibits functional agonist properties under
hypodopaminergic conditions. In addition to dopamine D2
partial agonism, aripiprazole acts as a partial agonist at some
5-HT receptor sub-types and as an antagonist at others.
At 5-HT1A receptors, aripiprazole is a partial agonist.
(Jordan S et al, 2002 ) Putative relationships have also been
postulated between 5-HT1A agonism and improvement in
depression, cognition and negative symptoms. (Millan MJ,
2000) Preclinical studies have demonstrated that aripiprazole
is an antagonist at 5-HT2A receptors. (McQuade RD, 2002)
Antagonism at 5-HT2A receptors may confer a favorable
effect on negative symptoms (Millan MJ 2000; Leysen JE
et al. 1993; Rao ML et al, 1994) and have an association
with low EPS liability. (Richelson E,1999)
In combination, the above studies suggest that aripiprazole
may function as a dopamine-serotonin system stabilizer, an
agent that acts as a functional antagonist or functional
agonist at dopamine and serotonin receptors depending on
the level of the relevant neurotransmitters in the environment
(Kane JM et al, 2002). The activity of aripiprazole at
dopamine and serotonin receptors suggests that the drug
may have overall efficacy against the symptoms of
schizophrenia, including both positive and negative
symptoms, with a low risk of side effects. This multicenter,
randomized, open labeled post-marketing study was
conducted to evaluate the efficacy and tolerability of
aripiprazole for the treatment of Indian patients with acute
relapse of schizophrenia or schizoaffective disorder.
Material & Method
Inclusion criteria
The clinical study required that participants were males
and non-pregnant, non-lactating females using suitable
contraceptive measures, aged 18 to 65 years, with a primary
diagnosis of acute relapse of schizophrenia or
schizoaffective disorder (DSM IV criteria).  The diagnostic
evaluation included the following: psychiatric evaluation
(DSM IV) for the diagnosis of schizophrenia or
schizoaffective disorder, history of the disease, and history
of response to treatment, a general clinical evaluation
(including medical history, physical examination, and current
symptoms), medication history during past week, Positive
And Negative Syndrome Scale (PANSS) (Kay SR et al,
1987) and the mean general psychopathology scores,
demographics, as well as vital signs, body weight,
electrocardiogram (ECG), and laboratory liver function
tests.
Exclusion criteria
Patients were excluded from the study if they had a
psychiatric disorder other than schizophrenia or
schizoaffective disorder, history of violence, history of
suicidal attempts or serious suicidal ideation, a clinically
significant neurologic abnormality other than tardive
dyskinesia or EPS, psychoactive drug abuse or dependence,
drug or alcohol abuse, or treatment with an investigational
drug within 4 weeks prior to washout phase. Patients were
also excluded if they had any other acute or unstable medical
condition. After complete description of the study to the
subjects or caregiver, written informed consent was
obtained.
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Study Duration & Follow -up
This randomized, open labeled, multicentric, 4-week post-
marketing study was conducted at 53 primary care centers
in India over the time period of August 2003 to April 2004.
Patients were screened for inclusion into the study at the
initial visit. Additionally, at screening the following data were
collected: demographics, clinical examination and prior
antipsychotic use. Patients were enrolled as per the study
inclusion criteria, provided they did not have any other
psychiatric disorder nor a significant abnormal laboratory
value, or any acute or unstable medical condition. Patients
included in the study were given 15mg of aripiprazole once
daily and treated for 4 weeks. At the end of 2 weeks, if the
patients showed reduction in PANSS total score ≥ 30% then
they were to continue treatment on same dosage. But, if
PANSS total score reduction was <30% then dosage was
to be increased to 30 mg once daily.
Patient Assessment
Clinical Efficacy
Treatment efficacy was assessed using the PANSS scale
and changes in general psychopathology. The PANSS
evaluation included the total score (30 items), the positive
subscale (7 items), and the negative subscale (7 items).
Symptom severity was rated using a 7-point scale. Then a
general psychopathology was evaluated for each patient.
Efficacy assessments were performed at screening
(baseline), and at the end of two weeks and four weeks of
treatment (days 14 and 28). The efficacy variable evaluated
included the mean change from baseline to week 4 in
PANSS total, PANSS positive and negative subscale &
the mean changes in score of general psychopathology.
Safety evaluation
Adverse events were monitored at the time of intervention
(Day 14) and at the end of the study medication. The status
and intensity of the reported adverse events were also
evaluated at the visit assessment. EPS were evaluated at
baseline and visits during the study using the Simpson-
Angus Scale (Simpson GM et al, 1970) and the Abnormal
Involuntary Movement scale (AIMS) (Guy W, 1976). Vital
signs were monitored at baseline and on days 14 and 28.
Twelve – lead ECGs, blood samples, and urinalysis were
assessed at baseline and at the end of therapy (at the
discretion of the investigators).
Study medication
The patients enrolled were given aripiprazole (15mg) and
use of psychotropic agents (other than study medication)
was prohibited throughout the treatment period of the study,
except for lorazepam for anxiety or insomnia or an
intramuscular lorazepam given in cases of emerging
agitation. Benztropine treatment was allowed for EPS, if
judged necessary by the investigators.
Study Analysis
Analysis of efficacy parameters was performed on an intent-
to-treat (ITT) basis using data obtained from each patient’s
last visit. The ITT population consisted of all patients with
at least 1 baseline and post baseline evaluation. The efficacy
parameters were evaluated by Analysis Of Variance
(ANOVA). Analysis of the vital parameters was also
evaluated by ANOVA. Statistical significance was reached
if the p value was less than or equal to 0.05.
Results
Patients
In this study 249 patients were enrolled. Baseline
characteristics for the randomized patients are listed in Table
1. Of the 249 randomized patients, 230 completed the 4-
week study period (ITT). Reason for discontinuation of
the remaining was that they lost to follow-up.
Patients included in the study were evaluated for efficacy
by assessing their baseline PANSS (total, positive, negative)
and general psychopathology (Table 2).
Efficacy Results
Aripiprazole doses produced significant improvement from
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Table 2: Clinical profile on administration
Variables Baseline (Mean+SE)
PANSS total score 92.63 + 30.6
PANSS positive subscale score 24.75 + 9.5
PANSS negative subscale score 22.49 + 10.79
General psychopathology 45.49 + 15.64
Table 1: Baseline Demographic Characteristics,





Age (18-60 yrs), 33.61 + 10.51
Mean + SE
Body weight (kg)
Mean + SE 60.51 + 11.42153
the baseline in the following measures: PANSS total score,
PANSS positive subscale score, PANSS negative subscale
score and general psychopathology. All treatment groups
demonstrated similar efficacy.
Average positive syndrome scale was 24.75 at baseline.
After treatment at the end of 2nd week mean score had a
significant reduction i.e. 28.8% and at the end of treatment
it was 47.3%. The mean negative syndrome scale was
22.49 at baseline evaluation. After treatment the mean score
had a reduction of 24.1% at 2nd week and 42.4% at the
end of treatment, which were statistically significant (Figure
1).
The mean total PANSS score at the end of 2nd week had
a reduction by 25.7% and 43.2% reduction at the end of
treatment from baseline (92.63), which were statistically
significant. (Fig. 2)
After treatment at the end of 2nd week the mean general
psychopathology score had a reduction of 25.7% from
baseline. At the end of treatment (week 4) reduction of




Aripiprazole treatment was well tolerated, with adverse
events generally mild-to-moderate in intensity and not
treatment- limiting. Overall, 19 (7 %) of the 249 randomized
patients failed to follow-up for the study. The most frequent
adverse events i.e. those occurring at an incidence of 5%
or more in the treatment group was not seen throughout
the study population. The incidences of the common side
effects were tremors (4.8%), restlessness (3.6%), akathisia
(3.2%), rigidity (2.8%), followed by 2% nausea/ vomiting,
headache, EPS and flatulence (Table 3) No patients in the
study group discontinued due to any of the adverse events.
The overall incidence of EPS related adverse events in the
study group were negligible.
Comparison of mean change in body weight in the study
group demonstrated no significant differences from baseline
evaluation. Also no significant changes in the QTc interval
were observed. There was no clinically significant
difference in vital signs or laboratory results in the study
group.
Discussion
The current study found that aripiprazole 15mg/day were
effective, safe, and well tolerated for the treatment of
patients with acute relapse of schizophrenia or
schizoaffective disorder. Aripiprazole produced significant
improvements compared with baseline for change in
PANSS total, PANSS positive & negative subscales and
general psychopathology scores. These efficacy data
clearly indicate that aripiprazole is effective in treating the
acute symptoms of schizophrenia. This data also further
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* p < 0.05 significant
Figure 2: Total PANSS score as compared to baseline
* p < 0.05 significant
*
*
Figure 1: Comparative PANSS Score (Positive & negative)
*
*
Figure 3: Mean Scores of General Psychopathology
*p < 0.05 significant
Table 3: Incidence of adverse events
(< 5% in the study group)








demonstrates that a dopamine D2 partial agonist can exhibit
clinically meaningful and sustained improvements in
schizophrenic symptoms, with sustained efficacy throughout
the 4-week duration of the study.
Treatment with aripiprazole was well tolerated at the
recommended doses. Adverse events were generally mild-
to moderate across all treatment groups and tended not to
be treatment limiting. Recent attention has been focused
on weight gain as a side effect of certain antipsychotic
drugs (Allison DB et al, 2001); weight gain due to
antipsychotics has important implications for health with
long-term use. In this study, a very modest mean increase
in body weight over the 4-week study period (range 0.2-
0.9 kg) that did not differ significantly from baseline was
recorded. Prolonged QTc interval, an ECG abnormality that
has been associated with certain antipsychotic drugs,
produces a small but increased risk of potentially dangerous
cardiac arrhythmias (Gury C et al, 2000). In the current
study, mean change in the QTc was not statistically different
from the baseline values. No patient in the study group
receiving aripiprazole experienced a clinically meaningful
change in QTc interval, further confirming as previous study
(Kane JM et al, 2002) that aripiprazole does not carry the
risk of potentially fatal ECG changes. Amongst the currently
available antipsychotic drugs, the major undesirable side
effect is to cause sedation, an effect that can negatively
impact a patient’s functioning and adherence with prescribed
therapy, especially in long-term treatment. The incidence
of sleep disturbance was minimal (0.4%). Extra pyramidal
side effects have been long associated with antipsychotic
drugs and have the potential to limit their tolerability and
effectiveness. The overall profile of aripiprazole for
parkinsonism, akathisia and dyskinesia was not significant
throughout the study period. The low risk of EPS as
observed in this study and other aripiprazole studies maybe
explained by its partial agonism at D2 receptors, in contrast
to the D2 antagonism of currently available antipsychotics.
The results of the present study indicate that aripiprazole
has considerable potential for the treatment of psychotic
disorders. The findings of the current study are consistent
with the clinical effects predicted by aripiprazole’s unique
pharmacodynamic profile, which includes potent D2 partial
agonist activity combined with partial agonism at 5-HT1A
receptors and antagonism at 5-HT2A receptors. These data
also support the conclusion that aripiprazole is the first agent
that is not a D2 antagonist to demonstrate a rapid onset of
action with sustained antipsychotic efficacy over 4 weeks.
The antipsychotic effects of aripiprazole given once daily
were achieved with excellent safety and tolerability profile,
with no evidence of marked EPS, weight gain, QTc
prolongation or sleep disturbances. These data suggest that
aripiprazole provides atypical antipsychotic efficacy with
minimal side effects and has the potential to lead to
increased treatment adherence and decreased relapsed
rates.
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